Cancer News and Research

Latest Cancer News and Research

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference.

15 Mar 2010

Landmark clinical trial examines effective treatment options for childhood epilepsy

One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.

15 Mar 2010

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported today (15 March) in the Biochemical Journal.

15 Mar 2010

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

Painful periods at early age doubles risk of endometriosis

Queensland Institute of Medical Research scientists have identified a new link between strong period pain experienced in adolescence and early adulthood and the risk of endometriosis.

15 Mar 2010

Keystone Symposia receives NIH grant for diversity initiatives

Keystone Symposia on Molecular and Cellular Biology is pleased to announce receipt of a $1.37 million, five-year MARC (Minority Access to Research Careers) Ancillary Training Activities grant from the National Institute of General Medical Sciences of the National Institutes of Health (NIH).

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

Prioritizing end of life care for cancer patients

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions.

15 Mar 2010

Medicare to cover OVA1 test

Vermillion, Inc. today announced that Medicare will cover OVA1™, a test to help assess the likelihood that an ovarian mass is benign or malignant. Highmark Medicare Services is the CMS contractor that will process Medicare claims for OVA1. Yesterday Highmark announced its decision to cover this new service.

12 Mar 2010

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

12 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Landmark clinical trial examines effective treatment options for childhood epilepsy

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Nanoparticles provide a targeted version of photothermal therapy for cancer

Painful periods at early age doubles risk of endometriosis

Keystone Symposia receives NIH grant for diversity initiatives

New study finds green tea extract may prevent Alzheimer's disease and dementia

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Prioritizing end of life care for cancer patients

Medicare to cover OVA1 test

Experts: Americans get too many tests, too much treatment

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

FDA accepts proposed proprietary name Exelbine for ADVENTRX Pharmaceuticals' ANX-530

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Antibiotics lower risk of developing gastric cancer

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in